The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity
ChemMedChem · 02.09.2024 · 19 (17)
DOI: 10.1002/cmdc.202400109 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 02.07.2024. Verfasst von Wenge Dong und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Elemento-Organic Chemistry and Frontiers Science Center for New Organic Matter, College of Chemistry, Nankai University, Tian…. Hauptthemen laut MEDLINE: Immunoconjugates. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 113 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Young Elite Scientist Sponsorship Program by CAST.
Abstract (Originalsprache)
Antibody‐drug conjugates (ADCs) consist of antibodies, linkers and payloads. They offer targeted delivery of potent cytotoxic drugs to tumor cells, minimizing off‐target effects. However, the therapeutic efficacy of ADCs is compromised by heterogeneity in the drug‐to‐antibody ratio (DAR), which impacts both cytotoxicity and pharmacokinetics (PK). Additionally, the emergence of drug resistance poses significant challenges to the clinical advancement of ADCs. To overcome these limitations, a variety of strategies have been developed, including the design of multi‐specific drugs with accurate DAR. This review critically summarizes the current challenges faced by ADCs, categorizing key issues and evaluating various innovative solutions. We provide an in‐depth analysis of the latest methodologies for achieving homogeneous DAR and explore design strategies for multi‐specific drugs aimed at combating drug resistance. Our discussion offers a current perspective on the advancements made in refining ADC technologies, with an emphasis on enhancing therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Elemento-Organic Chemistry and Frontiers Science Center for New Organic Matter, College of Chemistry, Nankai University, Tianjin, 300071, China.
ORCID-Profile: Chan Cao
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Young Elite Scientist Sponsorship Program by CAST
- Fundamental Research Funds for the Central Universities, Nankai University
Zitieren
APA
Dong, W., Wang, W., & Cao, C. (2024). The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity. ChemMedChem, 19(17). https://doi.org/10.1002/cmdc.202400109
Vancouver
Dong W, Wang W, Cao C. The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity. ChemMedChem. 2024;19(17). doi:10.1002/cmdc.202400109
BibTeX
@article{Dong2024,
author = {Dong, Wenge and Wang, Wanqi and Cao, Chan},
title = {The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity},
journal = {ChemMedChem},
year = {2024},
volume = {19},
number = {17},
doi = {10.1002/cmdc.202400109}
}
EUVIMED